Comparison of preoperative 5% povidone-iodine plus moxifloxacin versus 5% povidone-iodine alone on ocular surface bacterial flora: protocol for a randomized controlled trial Authors: Mary Ogbenyi Ugalahi, Olufunmilola Bamidele Makanjuola, Steve Oluwaseun Adebusoye, Bolutife Ayokunnu Olusanya Published: 2026 ABSTRACT BackgroundAcute postoperative endophthalmitis remains a rare but devastating complication of cataract surgery, most commonly arising from organisms originating in the patient’s conjunctival flora. While preoperative instillation of 5% povidone–iodine is universally accepted as standard prophylaxis, the additional benefit of preoperative topical antibiotics remains uncertain, particularly in settings with rising antimicrobial resistance and heterogeneous surgical practices. This study aims to determine whether the addition of topical moxifloxacin to 5% povidone–iodine increases the microbiological conversion rate from culture-positive to culture-negative conjunctival status immediately before cataract surgery, compared with 5% povidone–iodine alone.MethodsThis is a single-centre, parallel-group, superiority randomised controlled trial conducted at the University College Hospital, Ibadan, Nigeria. A total of 234 participants scheduled for elective cataract surgery will be randomised (1:1) to receive either preoperative topical moxifloxacin plus povidone–iodine or povidone–iodine alone. Conjunctival swabs will be collected at baseline and immediately prior to surgery. The primary outcome is the proportion of baseline culture-positive eyes that convert to culture-negative status before surgery. Secondary outcomes include residual culture positivity, bacterial species distribution, and antimicrobial susceptibility patterns. Effect estimates will be reported with 95% confidence intervals.DiscussionThis study is expected to clarify whether adjunctive topical moxifloxacin confers additional microbiological benefit beyond povidone–iodine alone. The findings will provide context-specific evidence to inform preoperative prophylactic strategies for cataract surgery, with implications for antimicrobial stewardship and evidence-based surgical guidelines.Trial registrationPan African Clinical Trials Registry (PACTR202509780471457). Prospectively registered; URL: https://pactr.samrc.ac.za/.Trial statusThe trial is still recruiting patients. Recruitment began on September 29, 2025, and is expected to be completed by late March.Protocol versionVersion 1.0, dated 16 July 2025.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12886-026-04881-y. Background and rationale Acute infective endophthalmitis is one of the most dreaded postoperative complications following cataract surgery worldwide due to its potential to cause irreversible blindness [1]. It is most commonly caused by microorganisms originating from the patient’s own ocular surface flora, particularly Staphylococcus species, which gain access to the intraocular space during or shortly after surgery. Consistent with global patterns, Staphylococcus epidermidis and Staphylococcus aureus remain the predominant causative pathogens, although other organisms—including Streptococcus, Pseudomonas, and a range of Gram-negative bacteria—are occasionally implicated [2–4]. Studies from Nigeria and other regions have reported a similar spectrum within the normal conjunctival flora, reinforcing the consistency of these organisms as both commensals and potential pathogens [5, 6]. Given this microbiological profile, effective perioperative prophylaxis remains essential to reducing the risk of inoculation and subsequent infection. To mitigate this risk, ophthalmologists employ a combination of prophylactic strategies, ranging from ocular surface decontamination to the use of antibiotics [7–10]. Standard preoperative antisepsis involves the instillation of 5% povidone-iodine into the conjunctival sac for approximately three minutes before surgery, along with the use of intracameral antibiotics. However, many surgeons complement this with topical antibiotics administered hours or days before surgery, as well as with subconjunctival antibiotics administered at the end of the procedure. Despite widespread adoption, the benefit of preoperative topical antibiotics remains controversial. Studies from Japan [8] and Israel [11] have suggested that there is no additional advantage of using preoperative antibiotics alongside povidone-iodine in reducing the incidence of postoperative endophthalmitis. Nevertheless, surveys continue to show that a subset of ophthalmologists globally, including in Nigeria, still employ this practice [9, 12]. In Nigeria, the use of preoperative topical antibiotics prior to cataract surgery remains prevalent. A national survey among ophthalmologists conducted during the 2017 annual conference revealed that many practitioners routinely instil topical antibiotics before surgery, despite the absence of local microbiological evidence to support this practice [2]. Over time preoperative topical-antibiotic practice in many Nigerian ophthalmic surgical units has shifted from prolonged courses to briefer preoperative dosing, often driven by logistics rather than evidence. Practice at the University College Hospital (UCH), Ibadan, exemplifies this heterogeneity: some surgeons prescribe topical antibiotics 24 h preoperatively while others rely solely on preoperative povidone–iodine antisepsis. Given the absence of nationally standardised guidance and the variable adoption of intracameral prophylaxis, this variability supports the need for a pragmatic, evidence-generating protocol to inform local practice. The persistence of topical antibiotic use in Nigeria raises two critical public health concerns. First, the continued empirical use of antibiotics without proven benefit contradicts antimicrobial stewardship principles, particularly in the context of rising global antibiotic resistance. Second, it increases the risk of promoting resistant strains within the ocular flora. The World Health Organization has emphasized the importance of rational antibiotic use since 2015, underscoring the need for evidence to guide such practices [13]. Therefore, in light of World Health Organization recommendations and the global effort to mitigate antimicrobial resistance, it is imperative to determine whether topical antibiotics confer any additional microbiological benefit beyond povidone-iodine alone in preventing postoperative infections. Cataract surgery is among the most frequently performed ophthalmic procedures in Nigeria, and as a national referral centre, University College Hospital, Ibadan performs a high volume of such surgeries annually. This positions it as a leading institution capable of generating evidence that can inform national and regional surgical guidelines. However, there is currently a paucity of data from Nigeria examining the impact of combining topical antibiotics with povidone-iodine on the conjunctival bacterial flora. This gap necessitates the proposed randomized trial, which aims to provide microbiological evidence to guide the rational use or non-use of preoperative topical antibiotics in Nigeria. Furthermore, current prophylactic practices vary widely across settings. In Nigeria, only 35% of ophthalmologists routinely use intracameral antibiotics, compared with 79% in France, whereas up to 43% report using preoperative topical antibiotics [2, 14]. This disparity in practice may reflect the lack of localized clinical evidence and the inherent challenges of conducting adequately powered trials to assess rare outcomes such as postoperative endophthalmitis. While intracameral antibiotics such as cefuroxime have demonstrated some efficacy in reducing endophthalmitis incidence [3, 4, 10], the value of preoperative topical antibiotics remains inconclusive [4, 15]. Consequently, surrogate microbiological outcomes—such as reductions in conjunctival bacterial load or culture positivity—represent pragmatic alternatives for evaluating the effectiveness of prophylactic interventions. The fluoroquinolone class, particularly moxifloxacin, remains the most frequently prescribed topical antibiotic for prophylaxis among Nigerian ophthalmologists [2]. Fluoroquinolones exert their bactericidal effect by inhibiting bacterial Deoxyribonucleic Acid gyrase and topoisomerase IV, thus preventing Deoxyribonucleic Acid replication and repair. They are active against a broad range of pathogens, including Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa, and members of the Enterobacteriaceae family. Their efficacy and safety have supported their continued use, yet the emergence of resistant strains—especially to ciprofloxacin—has raised significant concerns [16]. Moreover, fluoroquinolones have limited activity against fungi, which are an important cause of endophthalmitis, particularly in tropical settings [4]. Conversely, povidone-iodine possesses broad-spectrum antimicrobial properties against bacteria, fungi, viruses, and protozoa [17], and its non-selective mechanism minimizes the risk of microbial resistance. Upon tissue contact, it releases free iodine that disrupts cell membranes, enzymes, and nucleic acids, leading to microbial death. Clinical studies have demonstrated that povidone-iodine can reduce culture-positive conjunctival smears from 65 to 87% to as low as 3–30%% [6, 18]. However, whether the combination of povidone iodine with preoperative topical antibiotics yields further reduction in bacterial colonization remains uncertain—particularly within West Africa, where antimicrobial resistance patterns and ocular flora profiles may differ from other settings. Given these gaps in knowledge, this study aims to generate context-specific, evidence-based data comparing the effects of povidone iodine alone versus povidone iodine combined with topical moxifloxacin on conjunctival bacterial load prior to cataract surgery. The findings will contribute to national and regional guidelines promoting antibiotic stewardship in ophthalmic surgery. Ultimately, the trial seeks to balance effective infection control with the global imperative of minimizing unnecessary antibiotic use. Objectives To determine whether the addition of topical moxifloxacin to 5% povidone–iodine increases the proportion of eyes that convert from culture-positive at baseline to culture-negative immediately before cataract surgery, compared with 5% povidone–iodine alone. Secondary objectives include describing the spectrum of conjunctival bacterial species isolated at baseline and immediately prior to surgery, comparing the prevalence of residual culture positivity between treatment groups, and characterizing the antimicrobial susceptibility patterns of recovered organisms. Methods Patient and public involvement Although patients were not formally involved in the design, conduct, or reporting of this study, the trial question was developed partly in response to patient concerns about postoperative infection risk identified during cataract surgery counselling. Trial design This is a single-centre, parallel-group, superiority randomised controlled trial with a 1:1 allocation ratio comparing two preoperative antiseptic approaches. This protocol was developed and is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 guidelines [19]. A completed SPIRIT checklist is provided as Supplementary File 1. Setting, participants, and interventions The study will be conducted within the Department of Ophthalmology, University College Hospital, Ibadan, Nigeria. Trial activities will take place in the ophthalmology clinic, ward, and Ophthalmic theatre complex. Participants will include patients aged 5 years and older who are scheduled for elective cataract surgery—primarily Extracapsular Cataract Extraction (ECCE) and Manual Small Incision Cataract Surgery (MSICS)—at the Department of Ophthalmology, University College Hospital, Ibadan, Nigeria. Eligible participants must demonstrate willingness and ability to provide informed consent (or assent with parental consent for minors, as applicable) and adhere to the assigned preoperative topical moxifloxacin regimen. Exclusion criteria comprise: known allergy or hypersensitivity to fluoroquinolones or povidone-iodine, active ocular infection or inflammation such as infective conjunctivitis or dacryocystitis, and any periocular condition that may preclude safe cataract surgery. Individuals who have received topical steroids, or systemic or topical antibiotics within four weeks prior to enrolment, or a history of ocular surgery in the study eye, will also be excluded. Participants assigned to the experimental arm will receive topical 0.5% moxifloxacin eye drops (a total of seven doses on the day preceding surgery), instilled as a single drop every two hours between 8:00 a.m. and 8:00 p.m. On the day of surgery, two-hourly dosing will resume from 6:00 a.m. until the commencement of the procedure. This schedule constitutes an intensive preoperative loading regimen. As moxifloxacin exhibits enhanced bactericidal activity at higher peak concentrations [20], this intensified frequency is intended to achieve and maintain ocular surface and tissue concentrations well above the minimum inhibitory concentration for common ocular pathogens during the immediate 24-hour perioperative window. While some studies have occasionally employed four-times-daily regimens over longer preoperative periods (1–3 days) [21, 22], intensified short-term dosing strategies have also been described [23]. This approach reflects an intentionally intensified short-duration regimen informed by pharmacologic principles and local clinical practice in the absence of a universally standardised preoperative antibiotic protocol. In addition, they will receive the standard preoperative instillation of 5% povidone-iodine, applied as a single ocular surface preparation for three minutes, after which the solution will be rinsed off with 0.9% saline immediately before cataract surgery. Participants in the control arm will receive preoperative instillation of 5% povidone-iodine alone, administered in an identical manner as a single three-minute ocular surface application, followed by irrigation with 0.9% saline immediately prior to surgery. Povidone–iodine alone was selected as the comparator because it represents the internationally accepted standard-of-care preoperative antiseptic in ocular surgery. Its broad-spectrum antimicrobial efficacy and proven role in reducing postoperative endophthalmitis have been well established in multiple studies and guidelines [1, 4, 24]. Using povidone–iodine alone as the control therefore provides a scientifically, ethically and clinically appropriate benchmark against which to assess any additional benefit of the intervention. Participants will self-administer their assigned preoperative topical medications at home according to instructions provided by the study team. Adherence will be assessed during pre-surgical review by confirming the time and number of doses taken where applicable. No additional topical or systemic antibiotics or antiseptics will be permitted during the preoperative phase of the study. The use of any concurrent medications will be recorded at baseline and considered during subsequent data analyses. Treatment discontinuation will occur only in the event of drug-related allergy, hypersensitivity, or intolerance. Preoperative povidone–iodine ocular surface preparation will be administered by consultant ophthalmologists or senior ophthalmology residents using standard aseptic techniques. Instructions for preoperative topical moxifloxacin use will be provided by research assistants or study ophthalmologists using a standardized approach, after which participants in the intervention arm will self-administer the medication at home. All interventions will be delivered in accordance with routine clinical standards and established institutional practice, with personnel aware of the study protocol. Outcomes The primary outcome of this study is the microbiological conversion rate among participants who were culture-positive at baseline. Specifically, this represents the proportion of eyes that yielded a positive conjunctival bacterial culture prior to commencement of the assigned prophylactic regimen and subsequently became culture-negative immediately before surgery. This endpoint directly reflects the capacity of the intervention to eliminate ocular surface bacterial colonization. Several secondary outcomes will be evaluated to provide a comprehensive description of microbiological responses and comparative effects between treatment arms. These include the proportion of eyes that are culture-positive at baseline and the proportion that remain culture-positive immediately prior to surgery, presented both overall and stratified by treatment assignment. The spectrum of bacterial isolates and their distribution across groups will also be described, along with the antibiotic susceptibility profiles of recovered organisms. Safety and feasibility parameters will be descriptively summarized, including the incidence of any adverse drug reactions observed during the intervention period. Sample size The primary outcome is the proportion of eyes that are culture-positive at baseline and convert to culture-negative immediately prior to surgery (conversion rate). This endpoint was selected because residual post-povidone iodine positivity is low and conversion better captures differential microbiological clearance attributable to preoperative topical antibiotics. The sample size was computed using the two-proportion formula for comparing conversion rates:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{n}_{+}=\frac{{\left({Z}_{\frac{\alpha\:}{2}}+\:{Z}_{\beta\:}\right)}^{2}({p}_{1}\left(1-{p}_{1}\right)+{p}_{2}\left(1-{p}_{2}\right))}{{({p}_{1}-{p}_{2})}^{2}}$$\end{document} The parameters for this calculation were derived from a prospective controlled study by Carrim et al. [18], which demonstrated a baseline conjunctival culture positivity rate of 87%. In that study, the application of 5% povidone-iodine for three minutes reduced culture positivity from 87% to 30%, representing a conversion rate of approximately 66%. Consequently, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{p}_{1}=0.66$$\end{document} was used to represent the expected conversion rate in the control group. We anticipated an intervention conversion rate of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{p}_{2}=0.86$$\end{document}, corresponding to an absolute effect size of 20%. Using a two-sided significance level of 0.05 and 90% power, a requirement of 91 baseline culture-positive participants per study arm was determined. To account for the 87% baseline prevalence of conjunctival culture positivity reported in the reference population [18], and allowing for 10% attrition, a total of 117 participants per arm (234 participants overall) will be enrolled. The choice of 90% power reflects a conservative design approach to preserve adequate statistical power in the presence of potential variability in baseline culture positivity. Recruitment Participants will be consecutively recruited from cataract surgery listings. To avoid within-subject correlation and maintain statistical independence of observations, only one eye per participant will be included in the trial. For individuals scheduled for bilateral cataract surgery, the right eye will be selected a priori for eligibility assessment and randomization. Dedicated research assistants will coordinate enrolment to ensure sample size completion. Assignment of interventions A simple randomisation sequence of 234 entries (117 per arm) was generated using Python (NumPy library) with a fixed random seed (2025). Allocation concealment will be ensured using sequentially numbered opaque sealed envelopes prepared by an independent staff member. Research assistants will enrol eligible participants and assign the next sequential envelope. The study ophthalmologist will administer the allocated intervention. Blinding The microbiologist processing the swabs will be blinded to group allocation. All samples will be labelled with a unique study identifier, without reference to group allocation, to maintain blinding of the microbiologist. Participants and care providers cannot be blinded due to visible differences in the intervention schedule. Unblinding of the microbiologist will not be required, as microbiological outcomes are assessed after sample collection and prior to data analysis, and no safety-related decisions depend on laboratory allocation status. Data collection Data will be collected using standardized case report forms designed to capture participants’ demographic characteristics, relevant ocular history, baseline clinical findings, intervention adherence, and microbiological outcomes. Conjunctival specimens will be collected by one of two trained ophthalmology senior registrars at two specific time points: first, at the time of enrollment (baseline), and second, in the operating theatre on the day of surgery, immediately following the completion of the preoperative antiseptic preparation (after the 5% povidone-iodine has been rinsed with saline). Specimens will be obtained from the inferior fornix using sterile cotton-tipped swabs, with strict care taken to avoid contact with the eyelids or lashes to minimize contamination. Each swab will be immediately placed into a sterile transport tube and labelled with a unique study identifier, collection time, and eye laterality. All samples will be transported to the Medical Microbiology Laboratory, College of Medicine, University of Ibadan, within one hour of collection. Transport will occur under ambient conditions, ensuring that samples remain uncontaminated and viable for culture. Upon receipt in the laboratory, each conjunctival swab will be inoculated onto blood agar, chocolate agar, and MacConkey agar plates for culture. In addition, a direct smear will be prepared on a glass slide for Gram staining. The inoculated plates will be incubated at 37 °C—blood and chocolate agar in air supplemented with 5% CO₂, and MacConkey agar in ambient air—to allow aerobic microbial isolation. Plates will be examined after 24–48 h. Cultures with no visible growth will be reported as sterile. For plates demonstrating bacterial growth, isolates will be evaluated by Gram staining, colony morphology, and standard biochemical tests to determine organism identity in accordance with established microbiological protocols [25]. Participants will be followed up until the day of surgery, which coincides with primary outcome assessment. Given the short follow-up period, loss to follow-up is expected to be minimal. Where participants discontinue or deviate from the intervention, conjunctival culture data obtained prior to surgery will still be analysed where available. Antimicrobial susceptibility testing will be performed using the Kirby–Bauer disk diffusion method. Antibiotic panels will include amoxicillin, amoxicillin–clavulanic acid, cefuroxime, ceftriaxone, cefotaxime, gentamicin, ciprofloxacin, and/or levofloxacin, with final selection guided by organism type. Zone diameters will be interpreted using Clinical and Laboratory Standards Institute (CLSI) performance standards [26]. Data management and statistical analysis All data will be double-entered into a password-protected electronic database (REDCap, Vanderbilt University, Nashville, TN) with inbuilt range and logic checks to ensure internal validity and accuracy. Regular data audits and weekly backups will be conducted. The database will be accessible only to authorised study personnel. Data will be de-identified prior to analysis to maintain participant confidentiality. Data will be cleaned, verified, and analysed using Stata® (StataCorp, College Station, TX, USA). Descriptive statistics will summarise participants’ sociodemographic and clinical characteristics. Categorical variables will be presented as frequencies and percentages, while continuous variables will be summarised using means with standard deviations or medians with interquartile ranges, as appropriate based on distributional characteristics. Among eyes that are culture-positive at baseline, the proportion converting to culture-negative immediately prior to surgery will be estimated for each treatment arm. The primary measure of effect will be the absolute risk difference between the povidone–iodine plus moxifloxacin group and the povidone–iodine–only group, reported with 95% confidence intervals. Relative measures (risk ratios) will also be presented where informative. A two-sided chi-square test will be performed as a secondary inferential measure. Secondary analyses will estimate and compare the overall proportion of eyes that remain culture-positive immediately before surgery across treatment arms. The distribution of bacterial isolates will be summarised descriptively, and between-group differences will be assessed using chi-square or Fisher’s exact tests, with effect estimates and confidence intervals reported where applicable. Antimicrobial susceptibility patterns will be described to characterise local resistance profiles. Adverse events will be summarized descriptively by treatment arm. For continuous outcomes, between-group differences will be expressed as mean differences or as median differences estimated using the Hodges–Lehmann method, with corresponding 95% confidence intervals. Independent-sample t-tests or rank-based test statistics may be reported as supplementary inferential tools. Associations involving continuous covariates will be explored using correlation or regression models, with effect estimates and confidence intervals reported. Missing data will be quantified and patterns examined. Participants who do not undergo surgery and therefore do not have a conjunctival culture immediately prior to surgery will have missing primary outcome data and will be excluded from the primary outcome analysis. All analyses will be conducted as complete-case analyses. The extent of missing data will be reported transparently, including the number and proportion of participants with missing values for primary and secondary outcomes. Sensitivity analyses may be conducted to assess robustness of findings, including exclusion of participants with protocol deviations or incomplete adherence. Statistical analyses will focus on effect estimates and their 95% confidence intervals to quantify the magnitude and precision of associations. Two-sided p-values will be reported as complementary measures of statistical evidence, using a nominal significance level of 0.05. No interim analyses are planned. Trial oversight and monitoring The University College Hospital, Ibadan, serves as the coordinating site for the trial. Overall oversight is provided by the principal investigator and co-investigators, who are responsible for protocol adherence, data integrity, and participant safety. Given the minimal-risk nature of the intervention and the use of microbiological surrogate outcomes, no independent Data Monitoring Committee or steering committee was constituted. Study monitoring will be conducted through regular internal audits to verify compliance with the protocol, accuracy and completeness of data collection, and documentation of adverse events. Ethical oversight is provided by the University of Ibadan–University College Hospital Research Ethics Committee. Ethics and dissemination Ethical approval was obtained from the UI UCH Research Ethics Committee (Approval No. 25 0433) on 16 July 2025. The study will be conducted in accordance with the principles of the Declaration of Helsinki. Any substantial modification will be submitted to the ethics committee and updated in the trial registry. Written informed consent will be obtained from all participants in a language they understand before enrolment. Participant identifiers will be replaced with unique study codes; data will be stored in secured servers accessible only to authorised investigators. This study aims to provide evidence that may improve the safety and effectiveness of preoperative prophylaxis for participants undergoing cataract surgery. There is no envisaged harm to patients as the procedures are part of routine cataract care at the study site. Participants will continue to receive standard postoperative care. No financial compensation is planned, but adverse events directly attributable to study interventions will be managed at no cost. Participants who consent to participate in the study are free to withdraw their participation at any phase of the study without experiencing any negative consequences to their care. De-identified data and analytic code will be available to qualified researchers upon request after publication. Results will be presented at national and international conferences, submitted to a peer-reviewed journal and summarised on the institutional website and trial registry. Discussion This randomized controlled trial is designed to address a persistent and clinically relevant question in cataract surgery prophylaxis: whether the addition of preoperative topical antibiotics provides meaningful microbiological benefit beyond standard povidone–iodine antisepsis. While povidone–iodine remains the cornerstone of ocular surface disinfection, variability in the use of adjunctive topical antibiotics persists, local evidence is limited and antimicrobial stewardship considerations are increasingly important. By focusing on microbiological conversion among baseline culture-positive eyes, this study employs a pragmatic surrogate endpoint that is biologically relevant to perioperative ocular surface decontamination and feasible within the context of routine cataract surgery. This approach is consistent with prior microbiological investigations and enables comparative evaluation of antiseptic strategies without reliance on infrequent clinical endpoints or the need for substantially larger sample sizes. The trial is intentionally designed to reflect routine clinical practice at a high-volume tertiary centre in Nigeria, thereby enhancing its external validity. Allowing home administration of topical antibiotics in the intervention arm mirrors real-world practice and supports the generalisability of findings, albeit at the expense of complete control over adherence. To quantify and potentially account for this in sensitivity analyses, adherence check is implemented; however, the reliance on participant compliance remains a recognized limitation of the pragmatic trial design. Similarly, the single-centre design and lack of masking for participants and clinicians are recognised limitations but are mitigated by microbiological outcome assessment performed by blinded laboratory personnel. Importantly, the study also provides an opportunity to characterise contemporary conjunctival bacterial flora and antimicrobial susceptibility patterns in a Nigerian surgical population, generating data with relevance beyond the immediate trial question. These findings may inform local antibiotic policies, contribute to antimicrobial resistance surveillance, and guide rational prophylactic practices. Overall, this study aims to generate context-specific evidence to support evidence-based, stewardship-conscious preoperative care in cataract surgery. The results are expected to inform and refine preoperative prophylactic standards of care for cataract surgery locally, and other centres providing cataract surgical services. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material: Supplementary Table 1. SPIRIT 2025 checklist Supplementary Material: Supplementary Table 1. SPIRIT 2025 checklist